Dr. Reddy’s Laboratories launches Nivorz in India, marking the company’s entry into the country’s biosimilar immuno-oncology market. The product launch is presented by outlets as a milestone for Dr. Reddy’s as it expands its portfolio in a category focused on cancer immunotherapies.
Context for the launch is India’s growing immuno-oncology sector. One source notes that the market is estimated at about ₹3,900 crore in 2025 and is largely driven by checkpoint inhibitors such as nivolumab, pembrolizumab and toripalimab. Another outlet emphasizes the significance of the launch in terms of Dr. Reddy’s positioning within biosimilar immuno-oncology, while the underlying market backdrop remains the same.
Across the reports, the central shared point is the announcement of Nivorz and its role in expanding biosimilar immuno-oncology offerings in India. The sources differ mainly in emphasis—one provides market context, while others focus primarily on the company’s market entry and the significance of the launch.
